1
|
Ponnurangam S, Dandawate PR, Dhar A, Tawfik OW, Parab RR, Mishra PD, Ranadive P, Sharma R, Mahajan G, Umar S, Weir SJ, Sugumar A, Jensen RA, Padhye SB, Balakrishnan A, Anant S, Subramaniam D. Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. Oncotarget 2016; 7:3217-32. [PMID: 26673007 PMCID: PMC4823101 DOI: 10.18632/oncotarget.6560] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Accepted: 11/21/2015] [Indexed: 02/06/2023] Open
Abstract
Cancer stem cells (CSCs) appear to explain many aspects of the neoplastic evolution of tumors and likely account for enhanced therapeutic resistance following treatment. Dysregulated Notch signaling, which affects CSCs plays an important role in pancreatic cancer progression. We have determined the ability of Quinomycin to inhibit CSCs and the Notch signaling pathway. Quinomycin treatment resulted in significant inhibition of proliferation and colony formation in pancreatic cancer cell lines, but not in normal pancreatic epithelial cells. Moreover, Quinomycin affected pancreatosphere formation. The compound also decreased the expression of CSC marker proteins DCLK1, CD44, CD24 and EPCAM. In addition, flow cytometry studies demonstrated that Quinomycin reduced the number of DCLK1+ cells. Furthermore, levels of Notch 1–4 receptors, their ligands Jagged1, Jagged2, DLL1, DLL3, DLL4 and the downstream target protein Hes-1 were reduced. The γ-secretase complex proteins, Presenilin 1, Nicastrin, Pen2, and APH-1, required for Notch activation also exhibited decreased expression. Ectopic expression of the Notch Intracellular Domain (NICD) partially rescued the cells from Quinomycin mediated growth suppression. To determine the effect of Quinomycin on tumor growth in vivo, nude mice carrying tumor xenografts were administered Quinomycin intraperitoneally every day for 21 days. Treatment with the compound significantly inhibited tumor xenograft growth, coupled with significant reduction in the expression of CSC markers and Notch signaling proteins. Together, these data suggest that Quinomycin is a potent inhibitor of pancreatic cancer that targets the stem cells by inhibiting Notch signaling proteins.
Collapse
Affiliation(s)
- Sivapriya Ponnurangam
- Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,Department of Surgery, The University of Kansas Medical Center, Kansas City, KS 66160, USA
| | - Prasad R Dandawate
- Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,Department of Surgery, The University of Kansas Medical Center, Kansas City, KS 66160, USA
| | - Animesh Dhar
- Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,The University of Kansas Cancer Center, Kansas City, KS 66160, USA
| | - Ossama W Tawfik
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,The University of Kansas Cancer Center, Kansas City, KS 66160, USA
| | | | | | | | - Rajiv Sharma
- Piramal Life Sciences Inc, Goregaon East, Mumbai 400063, India
| | - Girish Mahajan
- Piramal Life Sciences Inc, Goregaon East, Mumbai 400063, India
| | - Shahid Umar
- Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,Department of Surgery, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,The University of Kansas Cancer Center, Kansas City, KS 66160, USA
| | - Scott J Weir
- Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,The University of Kansas Cancer Center, Kansas City, KS 66160, USA
| | - Aravind Sugumar
- Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,The University of Kansas Cancer Center, Kansas City, KS 66160, USA
| | - Roy A Jensen
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,The University of Kansas Cancer Center, Kansas City, KS 66160, USA
| | - Subhash B Padhye
- Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,Interdisciplinary Science and Technology Research Academy, Abeda Inamdar Senior College, Azam Campus, Pune, 411001, India
| | | | - Shrikant Anant
- Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,Department of Surgery, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,The University of Kansas Cancer Center, Kansas City, KS 66160, USA
| | - Dharmalingam Subramaniam
- Department of Molecular and Integrative Physiology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,Department of Surgery, The University of Kansas Medical Center, Kansas City, KS 66160, USA.,The University of Kansas Cancer Center, Kansas City, KS 66160, USA
| |
Collapse
|